Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Testicular germ cell tumours (GCTs) are the most common malignancy among young men. Management of GCTs relies on the serum tumour markers α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase, among other parameters. However, these tumour markers can only be detected at elevated levels in half of GCT patients. Circulating miR-371a-3p has emerged as a blood-based biomarker that can reliably detect macroscopic GCTs, aside from teratoma. Here we review the literature, describe the methodologies currently used to measure circulating miR-371a-3p, and discuss the following clinical scenarios in which miR-371a-3p may impact practice in the future: (1) men with an inconclusive small testicular mass; (2) response monitoring during chemotherapy; (3) postchemotherapy residual masses; and (4) follow-up after treatment with curative intent. PATIENT SUMMARY: We discuss the potential uses and promise, as well as current limitations, of a novel blood test that may improve care for men with testicular cancer. Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Citation

Christian D Fankhauser, Michelle M Nuño, Matthew J Murray, Lindsay Frazier, Aditya Bagrodia. Circulating MicroRNAs for Detection of Germ Cell Tumours: A Narrative Review. European urology focus. 2022 May;8(3):660-662

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 35537936

View Full Text